Live News EQUITY L impact Jul 20, 2026, 12:20 PM UTC

MRNA Raise PT to $67 from $49 but remain Neutral rated 49 ahead of the first potential Phase 3 mRNA cancer vaccine data @ GSCO

MRNA Raise PT to $67 from $49 but remain Neutral rated 49 ahead of the first potential Phase 3 mRNA cancer vaccine data @ GSCO

SquawkNews Newsroom

MRNA Raise PT to $67 from $49 but remain Neutral rated 49 ahead of the first potential Phase 3 mRNA cancer vaccine data @ GSCO